Search
R-30490
go.drugbank.com/drugs/DB09179ExperimentalR-30490 was found to be the most selective agonist for the mu opioid receptor out of all the fentanyl analogues tested, but it has never been introduced for medical use in humans, although the closely … It was first synthesized by Janssen Pharmaceutica as part of a structure-activity relationship study of fentanly and its derivatives.
Nemtabrutinib
go.drugbank.com/drugs/DB18866Investigationaltrial NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK
Lumateperone
go.drugbank.com/drugs/DB06077ApprovedInvestigational[A189093] It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology … [A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity.
Batroxobin
go.drugbank.com/drugs/DB09005InvestigationalThe MW of batroxobin is approximately 43,000 g/mol-1, and it contains 231 amino acids. Batroxobin is inactivated by alpha2-macroglobulin, but not anti-thrombin compounds. … Recombinant Batroxobin in relatively affordable and could be accessed by mass production.
International brands: Su Le JuanDihydroergocornine
go.drugbank.com/drugs/DB11273Approved[A32962] It is an artificial derivative of the crude extract of ergot and later purified, ergocornine. … [T190] It is found as one of the components in the ergoloid mesylate mixture. To know more about this mixture please refer to [DB01049]
Topiroxostat
go.drugbank.com/drugs/DB01685InvestigationalTopiroxostat and its metabolites are shown to be unaffected by renal complications, thus may be effective in patients with chronic kidney diseases [A19657]. … While [DB00437] is considered a first-line therapy in treating hyperuricemic conditions, it is often associated with side effects and ineffective in reducing uric acid levels under recommended dosing regimens
Isocarboxazid
go.drugbank.com/drugs/DB01247ApprovedIt is a monoamine oxidase inhibitor.[A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders. … [T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.
Bremelanotide
go.drugbank.com/drugs/DB11653Approved[L9635] Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141. … [A179683] Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women.
Streptococcus pneumoniae type 18c capsular polysaccharide antigen
go.drugbank.com/drugs/DB10335ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTORVibostolimab
go.drugbank.com/drugs/DB16420InvestigationalSubstudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK